What insurance policy changes affect code Z13?

There are 3 tracked policy changes affecting code Z13, including updates from Blue Shield of California, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z13?

Payers that have issued tracked updates for code Z13 include: Blue Shield of California, Aetna.

How do I get notified when code Z13 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z13. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z13?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

Z13 Insurance Policy Changes

code Z13 is referenced in 3 tracked payer policy changes from Blue Shield of California and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z13 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Shield of California · Effective Nov 1, 2026Medium impact
Carrier Screening for Genetic Diseases (2.04.107)
Blue Shield of California medical policy 2.04.107 treats targeted carrier screening for X-linked and autosomal recessive genetic diseases as medically necessary for individuals who are pregnant or considering pregnancy and are at increased risk of having offspring with one of these diseases. Targeted screening must meet one risk criterion (a first- or second-degree relative who is affected, a known carrier, or membership in a population with a carrier rate above the testing threshold) and all of six listed criteria. Those criteria include that alternative tests are not available or are less efficacious, that the genetic test has adequate clinical validity, and that previous carrier screening or individual targeted gene testing for the variant has not been performed. Non-targeted carrier screening panels may be considered medically necessary as an alternative to testing individual genes for individuals who are pregnant or considering pregnancy at any risk level, including high risk and average risk, when the listed criteria are met. Carrier screening is medically necessary only once per lifetime and should only be performed in adults. Targeted screening that does not meet the criteria, and non-targeted panels in all other situations, are considered investigational. The 11/01/2026 annual review made no change to the policy statement.
Aetna · Identified Oct 5, 2026Medium impact
Lead Testing (CPB 0553, reviewed 2026-08-28)
Aetna considers blood lead testing medically necessary for diagnosis of persons with signs and symptoms of lead poisoning and for pregnant or lactating women who have any listed lead exposure risk factor. Lead screening is covered for persons with occupational lead exposure and, as a preventive service, for children in listed high-risk groups. Measurement of lead in bone, hair, teeth, or urine is considered experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Lead Testing (CPB 0553, reviewed 2025-11-26)
Aetna considers blood lead testing medically necessary to diagnose people with signs or symptoms of lead poisoning, and for pregnant or lactating women who have any of the listed lead exposure risk factors. Routine blood lead testing for average-risk pregnant women without risk factors is not considered medically necessary. Lead screening is covered for persons with occupational lead exposure, which OSHA mandates, and as preventive care for children in high-risk groups under CDC, USPSTF, AAP and AAN guidance, while measuring lead in bone, hair, teeth or urine is considered experimental, investigational or unproven.

Watch Z13

Get one email when a payer policy names Z13, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Carrier Screening for Genetic Diseases (2.04.107)

Lead Testing (CPB 0553, reviewed 2026-08-28)

Lead Testing (CPB 0553, reviewed 2025-11-26)

What insurance policy changes affect code Z13?

Which payers have updated policy for code Z13?

How do I get notified when code Z13 policy changes?

Why do payers change policies for code Z13?